European Union - Czech - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infekce - antivirotika pro systémové použití - vitekta podávaný s inhibitorem proteázy a s jinými antiretrovirotiky je indikován k léčbě infekce u dospělých, kteří jsou nakaženi virem hiv-1 bez známých mutací v lidské imunodeficience virus 1 (hiv-1) spojených s rezistencí na elvitegravir.

European Union - Czech - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obezita - preparáty proti obezitě, diety - jako doplněk diety a fyzické aktivity k léčbě obézních pacientů (bmi 30 kg/m2), nebo pacientů s nadváhou (bmi 27 kg/m2) a s přidruženým rizikovým faktorem(y), jako je diabetes typu 2 nebo dyslipidémie (viz bod 5.

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

vuab pharma a.s., roztoky array - 2109 sodnÁ sŮl chloramfenikol-sukcinÁtu - prášek pro injekční roztok - 1g - chloramfenikol

European Union - Czech - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obezita - preparáty proti obezitě, diety - jako doplněk diety a fyzické aktivity k léčbě obézních pacientů (bmi 30 kg/m2), nebo pacientů s nadváhou (bmi 27 kg/m2) a s přidruženým rizikovým faktorem(y), jako je diabetes typu 2 nebo dyslipidémie (viz bod 5.

European Union - Czech - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

European Union - Czech - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanibu - karcinom, ledvinná buňka - antineoplastická činidla - fotivda je indikován k první linii léčby dospělých pacientů s pokročilým renálním karcinomem (rcc) a u dospělých pacientů, kteří jsou vegfr a mtor cesta-inhibitorem se po progresi onemocnění po předchozí léčbě cytokinové léčby pro pokročilého rcc. léčba pokročilého renálního karcinomu.

European Union - Czech - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamid - epilepsie - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

European Union - Czech - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

European Union - Czech - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastická činidla - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Czech Republic - Czech - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod